| |
| |
|
| Insider
Information: |
Schilke Tobin |
| Relationship: |
CFO |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
240,414 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$656,258 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
240,414 |
|
|
| Total
Value |
$656,258 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -194.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Achaogen Inc |
AKAO |
Chief Financial Officer |
2018-06-26 |
47,748 |
2016-07-05 |
0 |
Premium* |
|
|
Revance Therapeutics, Inc. |
RVNC |
CFO |
2024-03-18 |
192,666 |
2018-11-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2024-03-18 |
4 |
S |
$5.04 |
$47,204 |
D/D |
(9,361) |
192,666 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2024-03-15 |
4 |
D |
$5.31 |
$20,276 |
D/D |
(3,822) |
202,027 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2024-02-29 |
4 |
A |
$0.00 |
$0 |
D/D |
17,447 |
205,849 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
96,667 |
188,402 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-12-31 |
4 |
A |
$7.47 |
$3,242 |
D/D |
434 |
91,735 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
22,620 |
102,516 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-08-11 |
4 |
D |
$18.91 |
$212,076 |
D/D |
(11,215) |
91,301 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-07-03 |
4 |
AS |
$25.04 |
$42,593 |
D/D |
(1,701) |
79,896 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-06-30 |
4 |
A |
$15.61 |
$12,001 |
D/D |
769 |
81,597 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-06-02 |
4 |
AS |
$31.00 |
$15,500 |
D/D |
(500) |
80,828 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-06-01 |
4 |
AS |
$30.57 |
$82,570 |
D/D |
(2,701) |
81,328 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-05-15 |
4 |
S |
$34.55 |
$739,338 |
D/D |
(21,401) |
84,029 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-05-01 |
4 |
AS |
$31.70 |
$101,472 |
D/D |
(3,201) |
63,081 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-03-15 |
4 |
D |
$30.65 |
$114,600 |
D/D |
(3,739) |
69,483 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-03-09 |
4 |
S |
$31.59 |
$584,884 |
D/D |
(18,517) |
73,222 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-03-01 |
4 |
AS |
$33.50 |
$107,234 |
D/D |
(3,201) |
49,390 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-02-15 |
4 |
D |
$33.21 |
$69,243 |
D/D |
(2,085) |
52,591 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-02-01 |
4 |
AS |
$34.60 |
$110,755 |
D/D |
(3,201) |
54,676 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-01-20 |
4 |
AS |
$31.00 |
$31,000 |
D/D |
(1,000) |
57,877 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2023-01-09 |
4 |
AS |
$25.00 |
$100,525 |
D/D |
(3,701) |
58,877 |
0 |
% |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2022-12-31 |
4 |
A |
$12.18 |
$7,856 |
D/D |
645 |
62,578 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2022-12-15 |
4 |
D |
$21.50 |
$33,476 |
D/D |
(1,557) |
61,933 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2022-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
42,349 |
91,739 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
CFO |
• – – |
2022-06-30 |
4 |
A |
$11.75 |
$11,336 |
D/D |
965 |
63,490 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Chief Financial Officer |
• – – |
2022-03-15 |
4 |
D |
$15.79 |
$41,165 |
D/D |
(2,607) |
62,525 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
